[11C]AZ14132516

**[11C]AZ14132516 is a radiolabeled diagnostic agent developed by AstraZeneca for use in positron emission tomography (PET) imaging. It is primarily used as a radioligand to assess the biodistribution and binding characteristics of candidate drugs targeting the chemokine receptor CCR9 in the abdomen, particularly in studies involving Crohn’s disease. The compound enables visualization and quantification of intestinal inflammation and drug-target engagement during clinical trials of anti-inflammatory therapies such as AZD7798. Its mechanism involves specific binding to CCR9, allowing non-invasive imaging of target expression and pharmacodynamics in both healthy volunteers and patients with Crohn’s disease.**

Other names

[11C]AZ14132516AZ-14132516AZ14132516AZ 14132516